Commentary 10.1172/JCI138418

Th9 and Th17 cells: the controversial twins in cancer immunity

Chi Yan and Ann Richmond

Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee, USA. Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

Address correspondence to: Ann Richmond, 432 PRB, 2220 Pierce Avenue, Nashville, Tennessee 37232, USA. Phone: 615.343.7777; Email: ann.richmond@vanderbilt.edu.

Find articles by Yan, C. in: JCI | PubMed | Google Scholar |

Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee, USA. Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

Address correspondence to: Ann Richmond, 432 PRB, 2220 Pierce Avenue, Nashville, Tennessee 37232, USA. Phone: 615.343.7777; Email: ann.richmond@vanderbilt.edu.

Find articles by Richmond, A. in: JCI | PubMed | Google Scholar |

First published June 2, 2020 - More info

Published in Volume 130, Issue 7 on July 1, 2020
J Clin Invest. 2020;130(7):3409–3411. https://doi.org/10.1172/JCI138418.
© 2020 American Society for Clinical Investigation
First published June 2, 2020 - Version history

Th17 cells (producing IL-17) and Th9 cells (producing IL-9) exhibit functional plasticity, and their role in tumorigenicity is controversial. Th17/IL-17 and Th9/IL-9 exhibit critical, but often opposing, roles in tumor progression. In this issue of the JCI, Salazar et al. show that while IL-17 and IL-9 induced distinct but complementary molecular pathways, both cytokines also induced epithelial-mesenchymal transition (EMT) in lung cancer cells and promoted metastatic spreading. A key question before us now is whether IL-9 and IL-17 contribute to tumor progression in a sequential and stage-specific manner within the tumor microenvironment.

Preview pages

Reset
Page preview
3410 Page 3409 Back

Continue reading with a subscription.

A subscription is required for you to read this article in full. If you are a subscriber, you may sign in to continue reading.

Already subscribed?

Click here to sign into your account.

Don't have a subscription?

Please select one of the subscription options, which includes a low-cost option just for this article.

At an institution or library?

If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).

Problems?

Please try these troubleshooting tips.

  • Purchase this article
  • $10
  • Purchasing this article will give you full access for the calendar year.
  • Purchase article
  • Purchase Site Pass
  • $25
  • This will give you access to every article on the site for 24 hours.
  • Order site pass
  • Online subscription
  • $95
  • Individual online subscriptions give you full online access for the calendar year.
  • Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
  • Order Online
  • Print subscription
  • $830
  • Individual print subscriptions give you the print journal and full online access for the year.
  • Print + Online
  • JCI This Month subscription
  • $125
  • JCI This Month is a 16- to 20-page overview of the articles published each month
  • Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
  • *Price outside U.S. and Canada: $225.
  • JCI This Month + Online
Advertisement